Nitroxyl (HNO) as a vasoprotective signaling molecule

Antioxidants and Redox Signaling

Volumn 14, Issue 9, 2011, Pages 1675-1686

  Bullen, Michelle L ^a   Miller, Alyson A ^a   Andrews, Karen L ^b   Irvine, Jennifer C ^b   Ritchie, Rebecca H ^b   Sobey, Christopher G ^a   Kemp Harper, Barbara K ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CYCLIC GMP; ENDOTHELIUM DERIVED RELAXING FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; NITROXYL; OXYGEN; POTASSIUM CHANNEL; SUPEROXIDE; UNCLASSIFIED DRUG;

CELL GROWTH; CELL PROLIFERATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASODILATATION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; HUMANS; MODELS, BIOLOGICAL; NITROGEN OXIDES; SIGNAL TRANSDUCTION; VASODILATION;

EID: 79953790078     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3327     Document Type: Review

References (90)

1. Ahanchi SS, Tsihlis ND, and Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J Vasc Surg 45: A64-73, 2007.
2. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, and Hobbs AJ. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent downregulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101: 1386-1391, 2004. (Pubitemid 38182698)
3. Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, and Kemp-Harper BK. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpo-larizing factor in resistance arteries. Br J Pharmacol 157: 540-550, 2009.
4. Bartberger MD, Liu W, Ford E, Miranda K, Switzer CH, and Fukuto JM. The reduction potential of nitric oxide (NO) and its importance to NO biochemistry. Proc Natl Acad Sci USA 99: 10958-10963, 2002. (Pubitemid 34920861)
5. Bermejo E, Saenz DA, Alberto F, Rosenstein RE, Bari SE, and Lazzari MA. Effect of nitroxyl on human platelets function. Thromb Haemost 94: 578-584, 2005. (Pubitemid 41300855)
6. Berry C, Brosnan MJ, Fennell J, Hamilton CA, and Domin-iczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 10: 247-255, 2001. (Pubitemid 32221768)
7. Brain SD and Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84: 903-934, 2004. (Pubitemid 38823770)
8. 2\+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 37: 87-96, 2005. (Pubitemid 39497152)
9. Chirkov YY, Holmes AS, Chirkova LP, and Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 100: 129-134, 1999. (Pubitemid 29330010)
10. Choe CU, Lewerenz J, Fischer G, Uliasz TF, Espey MG, Hummel FC, King SB, Schwedhelm E, Boger RH, Gerloff C, Hewett SJ, Magnus T, and Donzelli S. Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neu-rochem 110: 1766-1773, 2009.
11. Costa G, Labadia A, Triguero D, Jimenez E, and Garcia- Pascual A. Nitrergic relaxation in urethral smooth muscle: Involvement of potassium channels and alternative redox forms of NO. Naunyn Schmiedebergs Arch Pharmacol 364: 516-523, 2001. (Pubitemid 33145091)
12. De Witt BJ, Marrone JR, Kaye AD, Keefer LK, and Kadowitz PJ. Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. Eur J Pharmacol 430: 311-315, 2001. (Pubitemid 33050056)
13. DeMaster EG, Redfern B, and Nagasawa HT. Mechanisms of inhibition of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide. Biochem Pharmacol 55: 2007-2015, 1998. (Pubitemid 28477471)
14. Dierks EA and Burstyn JN. Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem Pharmacol 51: 1593-1600, 1996.
15. Donzelli S, Espey MG, Flores-Santana W, Switzer CH, Yeh GC, Huang J, Stuehr DJ, King SB, Miranda KM, and Wink DA. Generation of nitroxyl by heme protein-mediated per-oxidation of hydroxylamine but not N-hydroxy-L-arginine. Free Radic Biol Med 45: 578-584, 2008.
16. Dora KA. Coordination of vasomotor responses by the en-dothelium. Circ J 74: 226-32, 2010.
17. Edwards G, Feletou M, and Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: A synopsis. Pflugers Arch 459: 863-879, 2010.
18. Ellis A, Li CG, and Rand MJ. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. Br J Pharmacol 129: 315-322, 2000. (Pubitemid 30072652)
19. Favaloro JL and Kemp-Harper B. Redox variants of NO (NO. and HNO) elict vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol Heart Circ Physiol 296: H1274-H1280, 2009.
20. Favaloro JL and Kemp-Harper BK. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Car-diovasc Res 73: 587-596, 2007. (Pubitemid 46073951)
21. Forstermann U. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349, 2008. (Pubitemid 351761708)
22. Fukuto JM, Bartberger MD, Dutton AS, Paolocci N, Wink DA, and Houk KN The physiological chemisty and biological activity of nitroxyl (HNO): The neglected, misunderstood, and enigmatic nitrogen oxide. Chem Res Toxicol 18: 790-801, 2005. (Pubitemid 40705445)
23. Fukuto JM, Chiang K, Hszieh R, Wong P, and Chaudhuri G. The pharmacological activity of nitroxyl: A potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263: 546-551, 1992.
24. Furchgott RF and Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980. (Pubitemid 11169009)
25. George A, Pushkaran S, Li L, An X, Zheng Y, Mohandas N, Joiner CH, and Kalfa TA. Altered phosphorylation of cyto-skeleton proteins in sickle red blood cells: The role of protein kinase C, Rac GTPases, and reactive oxygen species. Blood Cells Mol Dis 45: 41-45, 2010.
26. Harrison DG, Vinh A, Lob H, and Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol 10: 203-207, 2010.
27. Hecker M, Schott C, Bucher B, Busse R, and Stoclet JC. Increase in serum NG-hydroxy-L-arginine in rats treated with bacterial lipopolysaccharide. Eur J Pharmacol 275: R1-3,1995.
28. Hewett SJ, Espey MG, Uliasz TF, and Wink DA. Neurotoxicity of nitroxyl: Insights into HNO and NO biochemical imbalance. Free Radic Biol Med 39: 1478-1488, 2005. (Pubitemid 41547228)
29. Hobbs AJ, Fukuto JM, and Ignarro LJ. Formation of free nitric oxide from L-arginine by nitric oxide synthase: Direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci USA 91: 10992-10996, 1994. (Pubitemid 24349611)
30. Hoffman MD, Walsh GM, Rogalski JC, and Kast J. Identification of nitroxyl-induced modifications in human platelet proteins using a novel mass spectrometric detection method. Mol Cell Proteomics 8: 887-903, 2009.
31. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 20: 295-302, 2009.
32. Hughes MN and Cammack R Synthesis, chemistry, and applications of nitroxyl ion releasers sodium trioxodinitrate (An-geli's salt) and Piloty's acid. Methods Enzymol 310: 279-287,1999. (Pubitemid 28489790)
33. Irvine JC, Favaloro JL, and Kemp-Harper BK. NO∼ activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41: 1301-1307, 2003. (Pubitemid 36706081)
34. Irvine JC, Favaloro JL, Widdop RE, and Kemp-Harper BK. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49: 885-892, 2007. (Pubitemid 351664199)
35. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, and Kemp-Harper BK. Nitroxyl (HNO): The Cinderella of the nitric oxide story. Trends Pharmacol Sci 29: 601-608, 2008.
36. Jang EK, Azzam JE, Dickinson NT, Davidson MM, and Haslam RJ. Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by ni-troprusside. Br J Haematol 117: 664-675, 2002. (Pubitemid 34539245)
37. Irvine JC, Kemp-Harper BK, and Widdop RE. Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO. Antioxid Redox Signal 14: 1615-1624, 2011.
38. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, and Drum-mond GR. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 298: H24-32, 2010.
39. Keefer LK, Anderson LM, Diwan BA, Driver CL, Haines DC, Maragos CM, Wink DA, and Rice JM. Experimental tests of the mutagenicity and carcinogenicity of nitric oxide and its progenitors. Methods 7: 121-130, 1995.
40. Kemp-Harper B and Schmidt HH. cGMP in the vasculature. Handb Exp Pharmacol 191: 447-467, 2009.
41. Klemenska E and Beresewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol J 16: 11-19, 2009.
42. Li CG, Karagiannis J, and Rand MJ. Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle. Br J Pharmacol 127: 826-834, 1999. (Pubitemid 29295340)
43. Lopez BE, Shinyashiki M, Han TH, and Fukuto JM. Anti-oxidant actions of nitroxyl (HNO). Free Radic Biol Med 42: 482-491, 2007.
44. Ma XL, Gao F, Liu GL, Lopez BL, Christopher TA, Fukuto JM, Wink DA, and Feelisch M. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci USA 96: 14617-14622, 1999. (Pubitemid 30000699)
45. Martin W. Nitroxyl anion-The universal signalling partner of endogenously produced nitric oxide? Br J Pharmacol 157: 537-539, 2009.
46. Maurice DH and Haslam RJ. Molecular basis of the syner-gistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681, 1990. (Pubitemid 20171502)
47. Melichar VO, Kumar A, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, and Schmidt HH. Activity and expression of signalling enzymes downstream of nitric oxide is decreased in hypercholesterolemia-induced atherosclerosis in rabbits. Proc Natl Acad Sci USA 101: 16671-16676, 2004.
48. Miller AA, Budzyn K, and Sobey CG. Vascular dysfunction in cerebrovascular disease: Mechanisms and therapeutic intervention. Clin Sci (Lond) 119: 1-17, 2010.
49. Miller AA, Drummond GR, and Sobey CG. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther 111: 928-948, 2006. (Pubitemid 44160524)
50. Miller TW, Cherney MM, Lee AJ, Francoleon NE, Farmer PJ, King SB, Hobbs AJ, Miranda KM, Burstyn JN, and Fukuto JM. The effects of nitroxyl (HNO) on soluble guanylate cy-clase activity: Interactions at ferrous heme and cysteine thi-ols. J Biol Chem 284: 21788-21796, 2009.
51. Miranda K. The chemistry of nitroxyl (HNO) and implications in biology. Coordination Chem Rev 249: 433-455, 2005. (Pubitemid 40093751)
52. Miranda KM, Katori T, Torres de Holding CL, Thomas L, Ridnour LA, McLendon WJ, Cologna SM, Dutton AS, Champion HC, Mancardi D, Tocchetti CG, Saavedra JE, Keefer LK, Houk KN, Fukuto JM, Kass DA, Paolocci N, and Wink DA. Comparison of the NO and HNO donating properties of diazeniumdiolates: Primary amine adducts release HNO in vivo. J Med Chem 48: 8220-8228, 2005. (Pubitemid 43032530)
53. Miranda KM, Nims RW, Thomas DD, Espey MG, Citrin D, Bartberger MD, Paolocci N, Fukuto JM, Feelisch M, and Wink DA. Comparison of the reactivity of nitric oxide and nitroxyl with heme proteins. A chemical discussion of the differential biological effects of these redox related products of NOS. J Inorg Biochem 93: 52-60, 2003. (Pubitemid 36132133)
54. Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, Mitchell JB, Krishna MC, Colton CA, and Wink DA. Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401: 134-144, 2002. (Pubitemid 34848615)
55. Moncada S and Higgs EA. The discovery of nitric oxide and its role in vascular biology. BrJ Pharmacol 147: S193-S201,2006. (Pubitemid 43077277)
56. Mondoro TH, Ryan BB, Hrinczenko BW, Schechter AN, Vostal JG, and Alayash AI. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 112: 1048-1054, 2001. (Pubitemid 32322935)
57. Naughton P, Foresti R, Bains SK, Hoque M, Green CJ, and Motterlini R. Induction of heme oxygenase 1 by nitrosative stress. A role for nitroxyl anion. J Biol Chem 277: 40666-40674, 2002. (Pubitemid 35215648)
58. Nelli S, Hillen M, Buyukafsar K, and Martin W. Oxidation of nitroxyl anion to nitric oxide by copper ions. Br J Pharmacol 131: 356-362, 2000.
59. Norris AJ, Sartippour MR, Lu M, Park T, Rao JY, Jackson MI, Fukuto JM, and Brooks MN. Nitroxyl inhibits breast tumor growth and angiogenesis. Int J Cancer 122: 1905-1910, 2008. (Pubitemid 351413442)
60. Palmer RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987. (Pubitemid 17085822)
61. Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ, and Fukuto JM. The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the Janus face of NO. Pharmacol Ther 113: 442-458, 2007.
62. Paolocci N, Katori T, Champion HC, St. John ME, Miranda K, Fukuto JM, Wink DA, and Kass DA. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: Independence from /-adrenergic signalling. Proc Natl Acad Sci USA 100: 5537-5542, 2003. (Pubitemid 36542740)
63. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, Wink DA, and Kass DA. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98: 10463-10468, 2001. (Pubitemid 32803042)
64. Pino RZ and Feelisch M. Bioassay discrimination between nitric oxide (NO.) and nitroxyl (NO-) using L-cysteine. Biochem Biophys Res Commun 201: 54-62, 1994.
65. Plane F, Sampson LJ, Smith JJ, and Garland CJ. Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: Variable role for smooth muscle hyperpolarization. Br J Pharmacol 133: 665-672, 2001. (Pubitemid 32642872)
66. Pufahl RA, Wishnok JS, and Marletta MA. Hydrogen peroxide-supported oxidation of NG-hydroxy-L-arginine by nitric oxide synthase. Biochemistry 34: 1930-1941, 1995.
67. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, and Kemp-Harper BK. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 124: 279-300, 2009.
68. Ritchie RH, Lin EQ, Cao AH, Patel R, Kaye DM, and Kemp-Harper B. The NO redox sibling, nitroxyl (HNO), blocks cardiomyocyte hypertrophy via suppression of NADPH-oxidase. Circulation 116: S19-S20, 2007.
69. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones 39: 86-93,2007.
70. Ruetten H, Zabel U, and Schmidt HH. Down-regulation of soluble guanylate cyclase in young and ageing spontaneously hypertensive rats. Circ Res 85: 534-541, 1999. (Pubitemid 29431954)
71. Rusche KM, Spiering MM, and Marletta MA. Reactions catalyzed by tetrahydrobiopterin-free nitric oxide synthase. Biochemistry 37: 15503-15512, 1998. (Pubitemid 28516013)
72. Schmidt HH, Hoffman MD, Schindler U, Shutenko ZS, Cunningham DD, and Feelisch M. No NO from NO Synthase. Proc Natl Acad Sci USA 93: 14492-14497, 1996.
73. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper B, and Drummond GR. Nitric oxide supresses NADPH oxidase-dependent superoxide production by S-nitrosyla-tion in human endothelial cells. Cardiovasc Res 75: 349-358, 2007. (Pubitemid 46961925)
74. Selemidis S, Sobey CG, Wingler K, Schmidt HH, and Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120: 254-291, 2008.
75. Sobey CG and Faraci FM. Inhibitory effect of 4-aminopyr-idine on responses of the basilar artery to nitric oxide. Br J Pharmacol 126: 1437-1443, 1999. (Pubitemid 29142075)
76. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, and Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006. (Pubitemid 44330154)
77. Takahira R, Yonemura K, Fujise Y, and Hishida A. Dex-amethasone attenuates neutrophil infiltration in the rat kidney in ischemia=reperfusion injury: The possible role of nitroxyl. Free Radic Biol Med 31: 809-815, 2001. (Pubitemid 32835262)
78. Thomas SR, Witting PK, and Drummond GR. Redox control of endothelial function and dysfunction: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 10: 1713-1765, 2008.
79. 2\+ cycling. Circ Res 100: 96-104, 2007. (Pubitemid 46066777)
80. Tsihlis ND, Murar J, Kapadia MR, Ahanchi SS, Oustwani CS, Saavedra JE, Keefer LK, and Kibbe MR. Isopropylamine NONOate (IPA=NO) moderates neointimal hyperplasia following vascular injury. J Vasc Surg 51: 1248-1259, 2010.
81. Vanuffelen BE, Van Der Zee J, De Koster BM, Vansteveninck J, and Elferink JG. Intracellular but not extracellular conversion of nitroxyl anion into nitric oxide leads to stimulation of human neutrophil migration. Biochem J 330: 719-722, 1998. (Pubitemid 28111968)
82. Walter U and Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol 191: 533-548, 2009.
83. Wanstall JC, Jeffery TK, Gambino A, Lovren F, and Triggle CR. Vascular smooth muscle relaxation mediated by nitric oxide donors: A comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 134: 463-472, 2001. (Pubitemid 32977891)
84. Willoughby SR, Stewart S, Holmes AS, Chirkov YY, and Horowitz JD. Platelet nitric oxide responsiveness: A novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 25: 2661-2666, 2005. (Pubitemid 43732294)
85. Wink DA, Miranda KM, Katori T, Mancardi D, Thomas DD, Ridnour L, Espey MG, Feelisch M, Colton CA, Fukuto JM, Pagliaro P, Kass DA, and Paolocci N. Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: A novel redox paradigm. Am J Physiol Heart Circ Physiol 285: H2264-2276, 2003. (Pubitemid 37443041)
86. Winter P and Dora KA. Spreading dilatation to luminal perfusion of ATP and UTP in rat isolated small mesenteric arteries. J Physiol 582: 335-347, 2007. (Pubitemid 46993578)
87. Wong P, Hyun J, Fukuto JM, Shirota FN, DeMaster EG, Shoeman DW, and Nagasawa HT. Reaction between S-nitrosothiols and thiols: Generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry 37: 5362-5371, 1998. (Pubitemid 28241917)
88. Yuill KH, Yarova P, Kemp-Harper BK, Garland CJ, and Dora KA. A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries. Antioxid Redox Signal 14: 1625-1635, 2011.
89. Zeller A, Wenzl MV, Beretta M, Stessel H, Russwurm M, Koesling D, Schmidt K, and Mayer B. Mechanisms underlying activation of soluble guanylate cyclase by the HNO donor Angeli's Salt. Mol Pharmacol 76: 1115-1122, 2009.
90. Zembowicz A, Hecker M, Macarthur H, Sessa WC, and Vane JR. Nitric oxide and another potent vasodilator are formed from NG-hydroxy-L-arginine by cultured endothe-lial cells. Proc Natl Acad Sci USA 88: 11172-11176, 1991. (Pubitemid 21916002)